Creo Medical Group PLC Notice of Results

RNS Number : 9093L

Creo Medical Group PLC

25 April 2024

 

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Notice of Results

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, will announce its audited full year results for the year ended 31 December 2023 on Wednesday 15 May 2024.

 

Investor Presentation

 

Craig Gulliford, Chief Executive Officer, and Richard Rees, Chief Financial Officer, will provide a live presentation covering the full year results via the Investor Meet Company platform on Wednesday 15 May at 15:00 BST.

 

The presentation is open to all existing/potential shareholders and analysts. Questions can be submitted at any time during the live presentation.

 

Investors can sign up to Investor Meet Company at no additional cost and register in advance to meet Creo Medical Group plc via: https://www.investormeetcompany.com/creo-medical-group-plc/register-investor

 

Investors who already follow Creo Medical Group plc on the Investor Meet Company platform will automatically be invited.

 

-Ends-

 

Enquiries:

 

Creo Medical Group plc	www.creomedical.com
Richard Rees (CFO)	[phone]
Cavendish Capital Markets Limited	[phone]
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson (Sales)
Deutsche Numis (Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown	[phone]
Walbrook PR	Tel: [phone] or [e-mail]
Paul McManus / Sam Allen Phillip Marriage	Mob: [phone] [phone]

 

 

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NORZZLFLZZLLBBX